NCT03110276 - Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Healthy

Interventions

DRUG

EYP001a

10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).

DRUG

Placebo

Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.